These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 1416868)

  • 1. In vitro susceptibilities of Borrelia burgdorferi to five oral cephalosporins and ceftriaxone.
    Agger WA; Callister SM; Jobe DA
    Antimicrob Agents Chemother; 1992 Aug; 36(8):1788-90. PubMed ID: 1416868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of eight oral cephalosporins against Borrelia burgdorferi.
    Hunfeld KP; Rödel R; Wichelhaus TA
    Int J Antimicrob Agents; 2003 Apr; 21(4):313-8. PubMed ID: 12672576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative bacteriostatic and bactericidal activities of cefodizime against Borrelia burgdorferi sensu lato.
    Murgia R; Marchetti F; Cinco M
    Antimicrob Agents Chemother; 1999 Dec; 43(12):3030-2. PubMed ID: 10582905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents.
    Johnson RC; Kodner CB; Jurkovich PJ; Collins JJ
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2133-6. PubMed ID: 2073103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lyme disease: disparity between culture and polymerase chain reaction detection of Borrelia burgdorferi after exposure to ceftriaxone in vitro.
    Varde S; Wormser GP; Nowakowski J; Nadelman RB; Bittker S; Cooper D; Schwartz I
    Conn Med; 1999 Oct; 63(10):589-91. PubMed ID: 10578549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of an evernimicin (SCH27899) in vitro and in an animal model of Lyme disease.
    Pavia CS; Wormser GP; Nowakowski J; Cacciapuoti A
    Antimicrob Agents Chemother; 2001 Mar; 45(3):936-7. PubMed ID: 11181384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the mouse brain and other sites.
    Kazragis RJ; Dever LL; Jorgensen JH; Barbour AG
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2632-6. PubMed ID: 8913478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activities of fluoroquinolones against the spirochete Borrelia burgdorferi.
    Kraiczy P; Weigand J; Wichelhaus TA; Heisig P; Backes H; Schäfer V; Acker G; Brade V; Hunfeld KP
    Antimicrob Agents Chemother; 2001 Sep; 45(9):2486-94. PubMed ID: 11502519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of third-generation cephalosporins. Spirochetes.
    Luft B; Mariuz P
    Hosp Pract (Off Ed); 1991; 26 Suppl 4():34-9; discussion 53-4. PubMed ID: 1918214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotics and increased temperature against Borrelia burgdorferi in vitro.
    Reisinger E; Wendelin I; Gasser R; Halwachs G; Wilders-Truschnig M; Krejs G
    Scand J Infect Dis; 1996; 28(2):155-7. PubMed ID: 8792482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblasts protect the Lyme disease spirochete, Borrelia burgdorferi, from ceftriaxone in vitro.
    Georgilis K; Peacocke M; Klempner MS
    J Infect Dis; 1992 Aug; 166(2):440-4. PubMed ID: 1634816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colorimetric in vitro susceptibility testing of penicillins, cephalosporins, macrolides, streptogramins, tetracyclines, and aminoglycosides against Borrelia burgdorferi isolates.
    Hunfeld KP; Kraiczy P; Wichelhaus TA; Schäfer V; Brade V
    Int J Antimicrob Agents; 2000 Jun; 15(1):11-7. PubMed ID: 10856671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: a microdilution MIC method and time-kill studies.
    Dever LL; Jorgensen JH; Barbour AG
    J Clin Microbiol; 1992 Oct; 30(10):2692-7. PubMed ID: 1400969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of Borrelia afzelii strains to antimicrobial agents.
    Ruzić-Sabljić E; Podreka T; Maraspin V; Strle F
    Int J Antimicrob Agents; 2005 Jun; 25(6):474-8. PubMed ID: 15871918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents.
    Levin JM; Nelson JA; Segreti J; Harrison B; Benson CA; Strle F
    Antimicrob Agents Chemother; 1993 Jul; 37(7):1444-6. PubMed ID: 8363373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New colorimetric microdilution method for in vitro susceptibility testing of Borrelia burgdorferi against antimicrobial substances.
    Hunfeld KP; Kraiczy P; Wichelhaus TA; Schäfer V; Brade V
    Eur J Clin Microbiol Infect Dis; 2000 Jan; 19(1):27-32. PubMed ID: 10706176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kill kinetics of Borrelia burgdorferi and bacterial findings in relation to the treatment of Lyme borreliosis.
    Preac Mursic V; Marget W; Busch U; Pleterski Rigler D; Hagl S
    Infection; 1996; 24(1):9-16. PubMed ID: 8852456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of vancomycin against the spirochete Borrelia burgdorferi.
    Dever LL; Jorgensen JH; Barbour AG
    Antimicrob Agents Chemother; 1993 May; 37(5):1115-21. PubMed ID: 8517700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics.
    Baradaran-Dilmaghani R; Stanek G
    Infection; 1996; 24(1):60-3. PubMed ID: 8852472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity of Borrelia burgdorferi strains isolated in the Czech Republic.
    Janovská D; Hulínská D; Godová T
    Cent Eur J Public Health; 2001 Feb; 9(1):38-40. PubMed ID: 11243589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.